Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors
- 1 January 1992
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 30 (1), 21-24
- https://doi.org/10.1007/bf00686480
Abstract
The pharmacokinetics of carboplatin in cerebrospinal fluid (CSF) and plasma was studied in five children with brain tumors (four medulloblastomas and one ependimoblastoma) who underwent preirradiation treatment with carboplatin. Carboplatin pharmacokinetics was studied following the administration of 600 mg/m2 as a 1-h infusion. Four children were treated a few weeks after surgery, whereas one child with an unresectable tumor was treated prior to surgery. All patients had a ventricular-peritoneal CSF shunt connected to a subcutaneous reservoir. Total platinum and free carboplatin were measured. The mean AUC values for free carboplatin in CSF and plasma were 2.29±1.20 and 8.18±1.27 mg ml−1 min, respectively. The mean ratio of CSF AUC to plasma AUC was 0.28 (range, 0.17–0.46). Both plasma peak levels and AUC values showed limited interpatient variability. On the other hand, carboplatin levels in CSF showed substantial interpatient variability, with a>5-fold difference in peak levels and a 3-fold difference in AUC values being recorded. The interpatient difference in CSF pharmacokinetics may have been related at least in part to the different anatomical alterations induced by the surgical procedures or by the presence of a large tumor mass. In the four evaluable patients exhibiting macroscopic residual tumor, we observed one complete remission (CR) and two partial remissions (PR) following two cycles that consisted of two doses of 600 mg/m2 carboplatin given on 2 consecutive days (total dose, 1200 mg/m2) and were separated by a l-month interval. These results may give some indication as to the optimal dose and schedule for carboplatin administration in the treatment of primitive neuroectodermic tumors (PNET).Keywords
This publication has 13 references indexed in Scilit:
- Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screeningInvestigational New Drugs, 1988
- High dose carboplatin in the treatment of lung cancer and mesotherlioma: a phase I dose escalation studyEuropean Journal of Cancer and Clinical Oncology, 1987
- Plasma free platinum pharmacokinetics in patients treated with high dose carboplatinEuropean Journal of Cancer and Clinical Oncology, 1987
- Protein binding of five platinum compoundsCancer Chemotherapy and Pharmacology, 1986
- Rapid Determination of Platinum by Flameless Atomic Absorption Spectrophotometry Following the Administration of Cisplatin to Cancer PatientsTherapeutic Drug Monitoring, 1986
- High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urineCancer Chemotherapy and Pharmacology, 1986
- Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.1985
- HUMAN CENTRAL NERVOUS-SYSTEM DISTRIBUTION OF CIS-DIAMMINEDICHLOROPLATINUM AND USE AS A RADIOSENSITIZER IN MALIGNANT BRAIN-TUMORS1982
- Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II)Cancer Chemotherapy and Pharmacology, 1981
- Permeability Characteristics of Brain Adjacent to Tumors in RatsArchives of Neurology, 1975